Phase 1 Pancreatic Cancer Trial, Recruiting NCT05873699 Sponsor: M.D. Anderson Cancer Center Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT05873699
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have one or more cysts on their pancreas
  • People who are scheduled to have surgery or a tissue sample taken from a pancreatic cyst
  • People who are able to understand the study and are willing to sign a consent form
  • Both English-speaking and non-English-speaking people are welcome to participate

Who may not be able to join:

  • People for whom an MRI scan is not considered safe
  • People who have implanted devices (such as certain pacemakers or other electronic or mechanical implants) that are not compatible with MRI
  • People who have a known allergy to the MRI contrast dye called Gadavist
  • People who have a history of irregular heart rhythms
  • People who are pregnant or currently breastfeeding
  • Women of childbearing age who are sexually active and not using any form of contraception
  • People who have cognitive impairment that may affect their ability to independently understand and consent to participation
  • People who weigh more than 260 pounds (approximately 118 kg)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Florencia McAllister, MD, M.D. Anderson Cancer Center

Phone: (713) 745-0914

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
18 August 2023
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov